Metokarbamol

Metokarbamol
(IUPAC) ime
	(RS)-2-hidroksi-3-(2-metoksifenoksi)propil karbamat
Klinički podaci
AHFS/Drugs.com	Monografija
MedlinePlus	a682579
Identifikatori
CAS broj	532-03-6
ATC kod	M03BA03
PubChem	4107
DrugBank	DB00423
ChemSpider	3964
UNII	125OD7737X
KEGG	D00402
ChEMBL	CHEMBL1201117
Hemijski podaci
Formula	C11H15NO5
Mol. masa	241,241 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14) ; Key: GNXFOGHNGIVQEH-UHFFFAOYSA-N
Farmakokinetički podaci
Metabolizam	Hepatički
Poluvreme eliminacije	1,14–1,24 sata
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞-only (SAD) na slobodno(Kanada)
Način primene	Oralno, intravenozno

Metokarbamol je centralno delujuči miorelaksant koji se koristi za tretman spazama skeletalnih mišića. On je u prodaji pod imenom Robaxin.

Metabolism

Metokarbamol je karbamat gvajafenezina, ali se iz njega ne formira gvajafenezin kao metabolit, jer ne dolazi do metaboličke hidrolize karbamatne veze, već se metabolizmom faze I hidroksiluje i O-demetiluje prsten, i tome sledi konjugacija faze II. Svi glavni metaboliti su nehidrolizovani karbamati.^[7]^[8]

Hemija

Metokarbamol se može sintetisati iz gvajafenezin sukcesivnom reakcijom sa fosgenom i amonijakom.^[9]^[10]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948863. edit
↑ Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G. (1990). „Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals”. European Journal of Clinical Pharmacology 39 (2): 193–4. DOI:10.1007/BF00280060. PMID 2253675.
↑ Methocarbamol. In: DRUGDEX System [intranet database]. Greenwood Village, Colorado: Thomson Healthcare; c1974–2009 [cited 2009 Feb 10].
↑ Bruce RB, Turnbull LB, Newman JH. (1971). „Metabolism of methocarbamol in the rat, dog, and human”. J Pharm Sci 60 (1): 104–106. DOI:10.1002/jps.2600600120. PMID 5548215.
↑ R.S. Murphey, SAD patent 2770649 (1956)
↑ Yale, H. L.; Pribyl, E. J.; Braker, W.; Bergeim, F. H.; Lott, W. A. (1950). „Muscle-relaxing Compounds Similar to 3-(o-Toloxy)-1,2-propanediol.”. Journal of the American Chemical Society 72 (8): 3710. DOI:10.1021/ja01164a107.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948863. edit

[halflife-6] Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G. (1990). „Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals”. European Journal of Clinical Pharmacology 39 (2): 193–4. DOI:10.1007/BF00280060. PMID 2253675.

[7] Methocarbamol. In: DRUGDEX System [intranet database]. Greenwood Village, Colorado: Thomson Healthcare; c1974–2009 [cited 2009 Feb 10].

[metabolismBruce1971-8] Bruce RB, Turnbull LB, Newman JH. (1971). „Metabolism of methocarbamol in the rat, dog, and human”. J Pharm Sci 60 (1): 104–106. DOI:10.1002/jps.2600600120. PMID 5548215.

[9] R.S. Murphey, SAD patent 2770649 (1956)

[10] Yale, H. L.; Pribyl, E. J.; Braker, W.; Bergeim, F. H.; Lott, W. A. (1950). „Muscle-relaxing Compounds Similar to 3-(o-Toloxy)-1,2-propanediol.”. Journal of the American Chemical Society 72 (8): 3710. DOI:10.1021/ja01164a107.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]